Unknown statusInterventionalPhase 2Last updated Jan 25, 2018

Dendritic Cell-based Immunotherapy in Treatment Gastric Cancer

Activated Autologous Dendritic Cells by Autologous Tumor Cell Membrane Proteins in Treatment of Gastric Cancer

Overview

ClinicalTrials.gov ID: NCT03410732
Lead Sponsor: LanZhou UniversityOTHER
Brief Summary: Study objectives are to investigate the efficacy and safety of activated autologous dendritic cells (DCs) in treatment of gastric cancer. DCs are activated by the proteins from autologous tumor cell membrane and cytokines in vitro. The efficacy endpoints include objective response, immune-cell response, recurrent rate after a radical surgery, progression-free survival and overall survival, and the safety endpoints include adverse events, laboratory tests, ECG, ECOG-PT, etc.

Status

Overall Status: Unknown status
Start Date: Jul 1, 2017Actual
Primary Completion Date: Jul 1, 2020Estimated
Completion Date: Dec 1, 2020Estimated

Study Record Dates

First Submitted: Jan 16, 2018
First Submitted that Met QC Criteria: Jan 24, 2018
First Posted: Jan 25, 2018Actual
Last Update Submitted that Met QC Criteria: Jan 24, 2018
Last Update Posted: Jan 25, 2018Actual
Last Verified: Jan 2018

NCT02504229Unknown status

DC-CIK In Combination With Chemotherapy ( Gio / Oxaliplatin or Cisplatin ) Versus First-line Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma Randomized Controlled Phase II Clinical Study of Treatment

NCT03214939Unknown status

Autologous Antigen-activated Dendritic Cells in the Treatment of Patients With Colorectal Cancer

NCT02215837Unknown status

Study of Autologous Tumor Lysate-pulsed D-CIK Combined With Chemotherapy for Gastric Cancer

NCT04147078Recruiting

Personalized DC Vaccine for Postoperative Cancer

NCT02669719Unknown status

Cellular Immunotherapy Synergize Chemotherapy in Patients With Stage IV NSCLC

NCT03113019Unknown status

Autologous Antigen-activated Dendritic Cells in the Treatment of Patients With Breast Cancer